Drugs / LP-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06294275 | Sep 2022 → Aug 2023 | myelodysplastic syndrome | Longbio Pharma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LP-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06294275 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT06294275 ↗ |